{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T03:48:30Z","timestamp":1781063310955,"version":"3.54.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"39","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Novartis Vaccines"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.vaccine.2015.06.103","type":"journal-article","created":{"date-parts":[[2015,7,30]],"date-time":"2015-07-30T01:37:23Z","timestamp":1438220243000},"page":"5217-5224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: A phase III, randomized, multicentre, lot-to-lot consistency study"],"prefix":"10.1016","volume":"33","author":[{"given":"Kirsten P.","family":"Perrett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodie","family":"McVernon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"August","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Percell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Toneatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.06.103_bib0210","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/infdis\/126.5.514","article-title":"Immunologic response of man to group B meningococcal polysaccharide vaccines","volume":"126","author":"Wyle","year":"1972","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0215","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0220","first-page":"E251","article-title":"Annual report of the Australian Meningococcal Surveillance Programme, 2011","volume":"36","author":"Lahra","year":"2012","journal-title":"Commun Dis Intell Q Report"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2015.06.103_bib0225","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1016\/j.vaccine.2011.12.032","article-title":"The changing and dynamic epidemiology of meningococcal disease","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0230","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1179\/016164110X12644252260754","article-title":"Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention","volume":"32","author":"Safadi","year":"2010","journal-title":"Neurol Res"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0235","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/INF.0b013e3182706b89","article-title":"The disease burden of invasive meningococcal serogroup B disease in Canada","volume":"32","author":"Bettinger","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0240","unstructured":"England PH. Invasive meningococcal disease (laboratory reports in England): 2013\/2014 annual data by epidemiological year, vol 9(3), 23 Jan 2015."},{"key":"10.1016\/j.vaccine.2015.06.103_bib0245","first-page":"195","article-title":"Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba","volume":"14","author":"Sierra","year":"1991","journal-title":"NIPH Ann"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0250","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","article-title":"Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway","volume":"338","author":"Bjune","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0255","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.vaccine.2005.01.058","article-title":"The concept of tailor-made, protein-based, outer membrane vesicle vaccines against meningococcal disease","volume":"23","author":"Holst","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0260","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","article-title":"MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain","volume":"23","author":"Oster","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0265","first-page":"48","article-title":"Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease","volume":"122","author":"O\u2019Hallahan","year":"2009","journal-title":"N Z Med J"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0270","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","article-title":"Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing","volume":"287","author":"Pizza","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0275","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","article-title":"Vaccine potential of the Neisseria meningitidis 2086 lipoprotein","volume":"72","author":"Fletcher","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0280","series-title":"Poisson regression modelling of the effectiveness of the meningococcal B vaccine (MeNZB) updated results to December 2008, Technical Report New Zealand Ministry of Health","first-page":"90","author":"Arnold","year":"2010"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0285","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0290","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0295","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0300","doi-asserted-by":"crossref","first-page":"646","DOI":"10.4161\/hv.7.6.15482","article-title":"The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans","volume":"7","author":"Toneatto","year":"2011","journal-title":"Hum Vaccines"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0305","doi-asserted-by":"crossref","first-page":"781","DOI":"10.4161\/hv.7.7.15997","article-title":"Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults","volume":"7","author":"Toneatto","year":"2011","journal-title":"Hum Vaccines"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0310","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0315","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1016\/j.vaccine.2010.05.014","article-title":"Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus","volume":"28","author":"Giuliani","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0320","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1016\/S0264-410X(01)00050-0","article-title":"Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A\/C polysaccharide vaccine and vaccine-naive controls","volume":"19","author":"Borrow","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0325","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1185\/03007999909113370","article-title":"Kinetics of antibody response to Haemophilus influenzae type b vaccines. Pennridge Pediatric Associates","volume":"15","author":"Madore","year":"1999","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0330","doi-asserted-by":"crossref","first-page":"6974","DOI":"10.1016\/j.vaccine.2009.09.082","article-title":"Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adults","volume":"27","author":"de Voer","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0335","series-title":"Serum bactericidal antibody levels following quadrivalent conjugate (MenACWY-CRM) or serogroup B (4CMenB) meningococcal vaccines in a Phase 3 study to evaluate the effect of vaccination on pharyngeal carriage of N. meningitidis in young adults","author":"Dull","year":"2013"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0340","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/adc.2007.132571","article-title":"Phase II meningococcal B vesicle vaccine trial in New Zealand infants","volume":"94","author":"Jackson","year":"2009","journal-title":"Arch Dis Child."},{"key":"10.1016\/j.vaccine.2015.06.103_bib0345","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/01.inf.0000258697.05341.2c","article-title":"New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16\u201324 months","volume":"26","author":"Wong","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0350","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1128\/CVI.00167-07","article-title":"Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens","volume":"14","author":"Hosking","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0355","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/adc.2009.180596","article-title":"Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers","volume":"96","author":"Jackson","year":"2011","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0360","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","article-title":"Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease","volume":"21","author":"Holst","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0365","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/ije\/dyn228","article-title":"Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years","volume":"38","author":"Galloway","year":"2009","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0370","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction","volume":"364","author":"Trotter","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0375","series-title":"Read Rea Impact of a quadrivalent conjugate (MenACWY-CRM) or a serogroup B (4CMENB) meningococcal vaccine on meningococcal carriage in English university students. ESPID","year":"2013"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0380","series-title":"Novartis Novartis receives EU approval for Bexsero\u00ae, first vaccine to prevent the leading cause of life-threatening meningitis across Europe","year":"2013"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0385","series-title":"JCVI Position statement on use of Bexsero meningococcal B vaccine in the UK","year":"2014"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0390","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","article-title":"Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage","volume":"31","author":"Frosi","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0395","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.vaccine.2013.01.021","article-title":"A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults","volume":"31","author":"Marshall","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0400","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(12)70087-7","article-title":"Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Richmond","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0405","series-title":"Poster presented at: 9th Conference of the Meningitis Research Foundation, November 5\u20136, London, United Kingdom, 2013","article-title":"Safety, tolerability, and immunogenicity of an investigational meningococcal serogroup B bivalent rLP2086 vaccine when administered in regimens of 2 or 3 doses in healthy adolescent subjects aged 11 to 18 years","author":"Vesikari","year":"2013"},{"key":"10.1016\/j.vaccine.2015.06.103_bib0410","unstructured":"January 23, 2015 Approval Letter \u2013 BEXSERO, http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm431446.htm."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15009202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15009202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T15:26:08Z","timestamp":1537457168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15009202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":41,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0264410X15009202"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.06.103","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: A phase III, randomized, multicentre, lot-to-lot consistency study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.06.103","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}